Key Takeaways GSK plans $30B U.S. investment in R&D and supply chain infrastructure over the next five years.A $1.2B biologics flex factory in Pennsylvania will develop respiratory and cancer drugs.New AI and digital upgrades will enhance GSK's five U.S. manufacturing sites across four states.GSK plc (GSK) has unveiled a $30 billion investment plan in research and development (R&D) and supply chain infrastructure in the United States, which will be executed over the next five years.GSK’s latest initiative w ...